Monuril (Fosfomycin Trometamol)

Fosfomycin trometamol blocks the early step of bacterial cell‑wall synthesis by inhibiting the enzyme that forms N‑acetylmuramic acid, a key building block of peptidoglycan. Without this component, bacteria cannot construct a stable cell wall, leading to cell lysis and bacterial death.

The prescribed dose of Monuril is determined by the treating clinician based on the patient’s condition, age, renal function, and local guidelines. The medication is supplied as a single 3 g sachet that is reconstituted for oral administration.

Monuril is classified as Pregnancy Category B, indicating that animal studies have not shown risk to the fetus and there are no adequate human studies. It may be used during pregnancy only if the potential benefit justifies any potential risk. Limited data are available for breastfeeding; a risk‑benefit assessment should be performed.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Monuril. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Monuril offers a single‑dose oral regimen, which can improve adherence compared with multi‑day courses of trimethoprim‑sulfamethoxazole or fluoroquinolones. Its unique mechanism targets bacterial cell‑wall synthesis, providing activity against many resistant strains, though susceptibility testing remains important.

Monuril should be stored at ambient temperature below 25 °C, in its original packaging, and protected from moisture. The powder is stable under these conditions and does not require refrigeration.

The powder is reconstituted with a specified amount of water to create an oral solution. The patient drinks the solution after a full glass of water, typically on an empty stomach, to ensure optimal absorption.

Serious adverse events, although rare, include severe allergic reactions such as anaphylaxis, Stevens‑Johnson syndrome, toxic epidermal necrolysis, and Clostridioides difficile‑associated colitis. Patients should seek immediate medical attention if they develop rash, severe diarrhea, or signs of an allergic response.

Monuril should be avoided in individuals with a known hypersensitivity to fosfomycin or any component of the formulation. Caution is advised in patients with severe renal impairment, and it is not recommended for routine use in children unless specifically indicated by a qualified healthcare professional.